0 antall prosjekter

EIC-The European Innovation Council (EIC)

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose. In the NOVO project, we will develop the...

Tildelt: kr 17,8 mill.

Prosjektperiode: 2024-2028

Sted: Vestland

EIC-The European Innovation Council (EIC)

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

Tildelt: kr 25,2 mill.

Prosjektperiode: 2024-2028

Sted: Oslo

CL1-Health

Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers

Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers

Tildelt: kr 44,6 mill.

Prosjektperiode: 2024-2027

Sted: Oslo og 2 andre

MSCA-Marie Sklodowska-Curie Actions (MSCA)

DSTrain - Data Science Postdoctoral Training Programme

DSTrain is a 5-year postdoctoral programme that will award 36 postdoctoral fellowship positions of 36 months each in two calls over the programme period within the overarching frame of data science. The programme will train researchers and innovators with disciplinary, interdisciplinary and trans...

Tildelt: kr 52,1 mill.

Prosjektperiode: 2024-2028

Sted: Akershus og 12 andre

CL1-Health

ENTEROVIRUS-LINKED TYPE 1 DIABETES EXPOSED -MECHANISMS AND PREVENTION

ENT1DEP aims to define causal links between infections and NCDs by focusing on enterovirus (EV) infections and type 1 diabetes (T1D), a robust association without proof of causality. Causality is addressed by a multidisciplinary, multi-layer approach, using in-vitro and in-vivo models, unique hum...

Tildelt: kr 7,3 mill.

Prosjektperiode: 2024-2027

Sted: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Human - Centric Indoor Climate for Healthcare Facilities

Over 4 million hospital patients acquire a healthcare-associated infection (HAI) in the EU each year. Moreover, the global crisis of antimicrobial resistance means that HAI is posing an increasing cost and risk of mortality. There is clear evidence that airflow controls the dispersion and exposur...

Tildelt: kr 9,0 mill.

Prosjektperiode: 2024-2027

Sted: Trøndelag - Trööndelage

CL1-Health

The first European Digital Health Technology Assessment framework co-created by all stakeholders along the value chain

Digital health technologies (DHTs) are expected to improve both the quality and delivery of healthcare services for European societies while ensuring the sustainability of Europe`s healthcare systems. DHTs are also able to collect real-world data and evidence relevant for decision makers. However...

Tildelt: kr 21,5 mill.

Prosjektperiode: 2024-2027

Sted: Troms - Romsa - Tromssa og 2 andre

CL1-Health

The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics

The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics

Tildelt: kr 12,2 mill.

Prosjektperiode: 2024-2028

Sted: Oslo

CL1-Health

Development of a global diagnostic ecosystem for detecting and monitoring emergency-prone pathogens across species and in a unified way

We aim to contribute to global diagnostics and preparedness for the next health crisis by developing in vitro diagnostic devices and methodologies for application at the point-of-care. For this purpose, mature as well as novel technologies and assays will be developed, addressing all pandemic pre...

Tildelt: kr 9,4 mill.

Prosjektperiode: 2023-2027

Sted: Vestland

CL1-Health

Targeting Epstein-Barr Virus Infection for Treatment and Prevention of Multiple Sclerosis

Targeting Epstein-Barr Virus Infection for Treatment and Prevention of Multiple Sclerosis

Tildelt: kr 29,6 mill.

Prosjektperiode: 2023-2028

Sted: Rogaland og 5 andre

CL5-Climate, Energy and Mobility

From solar energy to fuel: A holistic artificial photosynthesis platform for the production of viable solar fuels

REFINE develops and demonstrates a system of artificial photosynthesis by combining both dark and light-dependent reactions for the direct production of high energy density and essential chemicals, such as alcohols. To achieve this, a direct hydrogen storage into hydrocarbons through CO2 capture ...

Tildelt: kr 21,8 mill.

Prosjektperiode: 2023-2027

Sted: Oslo og 2 andre

CL1-Health

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

Tildelt: kr 11,9 mill.

Prosjektperiode: 2023-2027

Sted: Rogaland

ERC-European Research Council (ERC)

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Tildelt: kr 1,7 mill.

Prosjektperiode: 2023-2025

Sted: Akershus og 2 andre

CL1-Health

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Tildelt: kr 18,2 mill.

Prosjektperiode: 2023-2028

Sted: Oslo

CL1-Health

Reconstruction and Computational Modelling for Inherited Metabolic Diseases

Reconstruction and Computational Modelling for Inherited Metabolic Diseases

Tildelt: kr 0,10 mill.

Prosjektperiode: 2023-2027

Sted: Oslo

CL1-Health

TOWARDS LARGE-SCALE ADAPTION AND TAILORED IMPLEMENTATION OF EVIDENCE-BASED PRIMARY CANCER PREVENTION PROGRAMMES IN EUROPE AND BEYOND

The high and growing global burden of cancer urges the need for effective implementation of primary cancer prevention (PCP) programmes targeting modifiable risk factors. However, evidence-based programmes with proven effectiveness under controlled environments often fail when implemented in the r...

Tildelt: kr 1,8 mill.

Prosjektperiode: 2023-2027

Sted: Vestland

CL1-Health

COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE

COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE

Tildelt: kr 3,2 mill.

Prosjektperiode: 2023-2026

Sted: Oslo

CL1-Health

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs

Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical benefit from the addition of CDK 4/6-inhibitors to endocrine therapy but with higher risk for adverse events and treatment discontinuation compared to younger pa...

Tildelt: kr 3,7 mill.

Prosjektperiode: 2023-2028

Sted: Akershus

CL1-Health

International Study for Treatment of Childhood Relapsed ALL 2020

International Study for Treatment of Childhood Relapsed ALL 2020

Tildelt: kr 1,1 mill.

Prosjektperiode: 2023-2028

Sted: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.

Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, h...

Tildelt: kr 2,9 mill.

Prosjektperiode: 2023-2026

Sted: Oslo

CL1-Health

Establishing of Cancer Mission Hubs: Networks and Synergies

Cancer- healthcare, research and innovation face core common challenges, such as fragmentation of initiatives and distancing from important stakeholders, requiring coordinated solutions. These challenges are recognized in Horizon Europe’s Cancer Mission Implementation Plan and in Europe’s Beating...

Tildelt: kr 3,7 mill.

Prosjektperiode: 2023-2026

Sted: Trøndelag - Trööndelage og 3 andre

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Combination therapy for the treatment of metastatic melanoma using magnetic nanoparticles

Metastatic melanoma is a hard-to-treat disease and it remains as one of the most worrisome cancer. There is an urgent need to improve the current therapies (chemotherapy, radiotherapy) that have a limited efficacy. A single therapy is not efficient to tackle metastatic melanoma and a combination ...

Tildelt: kr 3,0 mill.

Prosjektperiode: 2023-2027

Sted: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Determining Genetic Bases of Differential Response to Antipsychotics Using Patient-Derived Neurons

Schizophrenia (SCZ) affects 20 million people worldwide and antipsychotics remain the only effective pharmacological intervention. However, one-third of people with SCZ do not respond to first-line antipsychotic drugs. In the absence of clinical biomarkers to stratify SCZ subtypes, all individual...

Tildelt: kr 3,1 mill.

Prosjektperiode: 2023-2025

Sted: Vestland

WIDENING-Widening participation and spreading excellence

Diabetes, obesity and the Kidney

Chronic kidney disease is a major cause of morbidity and mortality in the EU. About 10-15% of the EU population has chronic kidney disease (CKD) and this number is expected to increase in the future decades. Diabetes is today the main cause of CKD in the EU: about, 30% of the cases with dialysi...

Tildelt: kr 2,9 mill.

Prosjektperiode: 2023-2025

Sted: Oslo

ERC-European Research Council (ERC)

Final act of the autophagy symphony: Whole-organism orchestration of autophagy termination

When an organism experiences physiological stresses, such as nutrient starvation, it activates several mechanisms to promote its survival. One of these mechanisms is autophagy, which is a catabolic pathway conserved from yeast to man that functions as a recycling system during normal physiology, ...

Tildelt: kr 15,2 mill.

Prosjektperiode: 2023-2027

Sted: Oslo

CL1-Health

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Tildelt: kr 3,5 mill.

Prosjektperiode: 2023-2025

Sted: Vestland

CL1-Health

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe

Tildelt: kr 7,6 mill.

Prosjektperiode: 2023-2026

Sted: Oslo

CL1-Health

Maximising Impact of Prescription Drugs in Rheumatoid Arthritis

Maximising Impact of Prescription Drugs in Rheumatoid Arthritis

Tildelt: kr 21,1 mill.

Prosjektperiode: 2022-2027

Sted: Oslo

EIC-The European Innovation Council (EIC)

Supervised morphogenesis in gastruloids

Supervised morphogenesis in gastruloids

Tildelt: kr 13,6 mill.

Prosjektperiode: 2022-2027

Sted: Oslo

CL1-Health

Fostering a European Research Area for Health Research

Fostering a European Research Area for Health Research

Tildelt: kr 15,8 mill.

Prosjektperiode: 2022-2029

Sted: Akershus og 2 andre